Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanoma.

Fifty-seven patients with metastatic melanoma were treated with interleukin 2 (IL-2) 7.8 MIU m-2 day-1 as a continuous infusion for 4 days combined with interferon alpha (IFN-alpha) 6 MIU m-2 day-1 subcutaneously on days 1 and 4. The cycle was repeated every 2 weeks for a maximum number of 13 cycles...

Descripción completa

Detalles Bibliográficos
Autores principales: Kruit, W. H., Goey, S. H., Calabresi, F., Lindemann, A., Stahel, R. A., Poliwoda, H., Osterwalder, B., Stoter, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033853/
https://www.ncbi.nlm.nih.gov/pubmed/7779731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033853/
https://www.ncbi.nlm.nih.gov/pubmed/7779731

Ejemplares similares